US 11,667,708 B2
Anti-human beta klotho antibody or binding fragment thereof and methods of their use
Kalyani Mondal, San Mateo, CA (US); Betty Chan Li, Millbrae, CA (US); Yu Chen, Foster City, CA (US); Taruna Arora, Palo Alto, CA (US); Hugo Matern, San Mateo, CA (US); and Wenyan Shen, Redwood City, CA (US)
Assigned to NGM Biopharmaceuticals, Inc., South San Francisco, CA (US)
Filed by NGM Biopharmaceuticals, Inc., South San Francisco, CA (US)
Filed on Aug. 28, 2020, as Appl. No. 17/5,675.
Application 17/005,675 is a continuation of application No. 15/748,111, granted, now 10,800,843, issued on Oct. 13, 2020, previously published as PCT/US2016/044704, filed on Jul. 29, 2016.
Claims priority of provisional application 62/198,664, filed on Jul. 29, 2015.
Prior Publication US 2021/0115133 A1, Apr. 22, 2021
Int. Cl. A61K 39/395 (2006.01); C07K 16/28 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/28 (2013.01) [A61K 39/001132 (2018.08); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/52 (2013.01); C07K 2317/565 (2013.01); C07K 2317/92 (2013.01)] 59 Claims
 
1. An antibody or fragment thereof that binds human beta-klotho, wherein the antibody or fragment thereof comprises: a heavy chain variable region (VH) comprising a VH complementarity determining region (CDR)1 comprising the amino acid sequence of SEQ ID NO:32, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:29, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:3; and a light chain variable region (VL) comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO:4, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:13, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:6.